Natural product-derived PD-1 pathway blockade for Human cancer therapy: Ganoderma lucidum extract decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 7/December/2016, 10.27 pm

Natural product-derived therapy for Myocardial Infarction: Kavalactone (2′,6′-dichloro-5-methoxymethyl-5,6-dehydrokawain), found in herb kava kava, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up-regulation of PNUTS , 7/December/2016, 11.18 am
December 7, 2016
Natural product-derived cardioprotective therapy: Icarrin, isolated from Horny-goat-weed, increases Spermidine levels, augments autophagy, mitophagy and mitochondrial respiration, lowers systemic blood pressure, and protects it from cardiac diseases via down regulation of its target gene, 7/December/2016, 10.42 pm
December 7, 2016
Show all

Introduction:What they say

A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.” This study was published in the 16 February 2016 issue of Immunity (one of the best journals in Immunology with an impact factor of 20+) by Prof Rudd CE, Taylor A and others.


What we say

price-100[easy_payment currency=”USD”]

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived PD-1 pathway blockade for Human cancer therapy:  Ganoderma lucidum extract decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year.


Research Findings

This study suggests a natural product-based Human cancer therapy. Ganoderma lucidum extract, by increasing the expression of its target gene, it may suppress the expression of Glycogen synthase kinase 3-β (figure 1).

ganoderma_lucidum

Figure1. Ganoderma lucidum. Ganoderma lucidum extract enhances cytolytic function of Cytotoxic T-lymphocytes, augments anti-tumor activity, and inhibits metastatic cancer progression via downregulation of Glycogen synthase kinase-3β and PD-1

Thereby, it may: (a) increase transcription factor T-bet expression; (b) inhibit co-inhibitory receptor PD-1 expression;  (c) increase CD8(+) cytotoxic T lymphocyte function; (d) augment anti-tumor activity; & (e) inhibit metastatic cancer progression.


Therapeutic opportunity

Thus, pharmacological formulations encompassing “Ganoderma lucidum extract or an active compound isolated from it” may be used to inhibit the progression of tumors.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $100

Undisclosed information: How Ganoderma lucidum extract suppresses the expression of PD-1 and augments anti-tumor immunity

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Citation: Boominathan, L., Natural product-derived PD-1 pathway blockade for Human cancer therapy:  Ganoderma lucidum extract decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 7/December/2016, 10.26 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.